AR128074A1 - Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales - Google Patents

Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales

Info

Publication number
AR128074A1
AR128074A1 ARP220103558A ARP220103558A AR128074A1 AR 128074 A1 AR128074 A1 AR 128074A1 AR P220103558 A ARP220103558 A AR P220103558A AR P220103558 A ARP220103558 A AR P220103558A AR 128074 A1 AR128074 A1 AR 128074A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
animals
injectable pharmaceutical
respiratory diseases
Prior art date
Application number
ARP220103558A
Other languages
English (en)
Spanish (es)
Inventor
Chen Wang
- Meyer Thorsten Chao
Ralf Warrass
Joachim Ullrich
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR128074A1 publication Critical patent/AR128074A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ARP220103558A 2021-12-24 2022-12-22 Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales AR128074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21217704 2021-12-24

Publications (1)

Publication Number Publication Date
AR128074A1 true AR128074A1 (es) 2024-03-20

Family

ID=79601675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103558A AR128074A1 (es) 2021-12-24 2022-12-22 Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales

Country Status (9)

Country Link
US (1) US20250057790A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452226A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024544415A (cg-RX-API-DMAC7.html)
CN (1) CN118632684A (cg-RX-API-DMAC7.html)
AR (1) AR128074A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022420882A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242451A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024007862A (cg-RX-API-DMAC7.html)
WO (1) WO2023118557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
AR134777A1 (es) 2023-12-21 2026-04-01 Intervet Int Bv Formas cristalinas de sales de (s)-n-(3-amino-1-(hidroxiamino)-3-metil-1-oxobutan-2-il)-4-((4-(((2-metoxietil)amino)metil)fenil)etinil)benzamida
CN122422289A (zh) 2023-12-21 2026-07-17 英特维特国际股份有限公司 (s)-n-(3-氨基-1-(羟基氨基)-3-甲基-1-氧代丁-2-基)-4-((4-(((2-甲氧基乙基)氨基)甲基)苯基)乙炔基)苯甲酰胺盐的结晶形式的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
JP7082445B2 (ja) 2016-12-23 2022-06-08 インターベット インターナショナル ベー. フェー. ウシ又はブタの呼吸器疾患を治療するための化合物

Also Published As

Publication number Publication date
CA3242451A1 (en) 2023-06-29
WO2023118557A1 (en) 2023-06-29
US20250057790A1 (en) 2025-02-20
AU2022420882A1 (en) 2024-06-20
MX2024007862A (es) 2024-07-09
JP2024544415A (ja) 2024-11-29
EP4452226A1 (en) 2024-10-30
CN118632684A (zh) 2024-09-10

Similar Documents

Publication Publication Date Title
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
PY2121402A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CL2024001828A1 (es) Composición farmacéutica que comprende un compuesto de quinazolina
ECSP22091313A (es) Compuestos heterocíclicos como anthelmínticos
BR0316397A (pt) Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
MX2024007862A (es) Una composicion farmaceutica inyectable para el tratamiento de enfermedades respiratorias en animales.
HN2000000115A (es) Formulacion de sal comun y moxifloxacina
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
CO2022015630A2 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
ECSP22036502A (es) Inhibidores del factor d del complemento para administraci?n oral
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR120931A1 (es) Fungicidas para prevenir y controlar patógenos fúngicos
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
CL2025001080A1 (es) Método para preparar maribavir.
CL2024002500A1 (es) Inhibidores de proteínas de unión a emopamilo y usos de estos
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas
ES2144452T3 (es) Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia.
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.